scholarly journals Serotonin syndrome in patients with headache disorders

2017 ◽  
pp. bcr-2017-221383 ◽  
Author(s):  
Sanjay Prakash ◽  
Banshi Adroja ◽  
Haresh Parekh
Keyword(s):  
Serotonin Syndrome ◽  
Headache Disorders

Headache as a presenting feature in patients with serotonin syndrome: A case series

Cephalalgia ◽  
2013 ◽  
Vol 34 (2) ◽  
pp. 148-153 ◽  
Author(s):  
Sanjay Prakash ◽  
Pooja Belani ◽  
Aditi Trivedi
Keyword(s):  
Clinical Features ◽  
Serotonin Syndrome ◽  
Medication Overuse Headache ◽  
Case Series ◽  
Headache Disorders ◽  
Drug Induced ◽  
Positive Effects ◽  
Life Threatening ◽  
Serotonergic Drugs ◽  
Acute Headache

Introduction Serotonin syndrome (SS) is a drug-induced constellation of various clinical features that result from excess central serotonergic tone. The clinical features range from barely perceptible to life-threatening conditions. Cases We describe four patients with acute headache (four days to three weeks) who were receiving serotonergic drugs for other indications. There was a temporal relation between the administration of the serotonergic drugs and the development of the headaches. All four patients fulfilled the Hunter Serotonin Toxicity Criteria for SS. In parallel, two patients fulfilled the Sternbach’s criteria for SS. Discontinuation of the serotonergic drugs and the administration of cyprohepatadine led to complete improvement in three to seven days in all four patients. Discussion A review of the literature suggests that some overlaps exist in the pathophysiology between SS and headache disorders, including medication-overuse headache. The overlap is also in the management. The drugs found to be effective in SS (cyproheptadine, chlorpromazine, olanzapine, etc.) are also known to have positive effects on some headache disorders. Conclusion Physicians should consider the diagnosis of SS in patients with new onset or worsening headache after the addition of serotonergic drugs, especially in the presence of objective signs on examination suggestive of the disorder such as tremor, fever, hyperreflexia, diaphoresis or tachycardia.

FDA Advisory Warns of Serotonin Syndrome

2006 ◽  
Vol 34 (11) ◽  
pp. 8
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Serotonin Syndrome

Serotonin Syndrome: A Case Report.

2016 ◽  
Vol 12 (01) ◽  
pp. 58-61
Author(s):  
Nantawan Tinroongroj ◽  
Apichard Sukonthasarn
Keyword(s):  
Case Report ◽  
Serotonin Syndrome

Neurobehavioral Consequences Associated with Long Term Tramadol Utilization and Pathological Mechanisms

2020 ◽  
Vol 18 (10) ◽  
pp. 758-768 ◽  
Author(s):  
Khadga Raj ◽  
Pooja Chawla ◽  
Shamsher Singh
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Syndrome ◽  
Dopamine Synthesis ◽  
Synthetic Analog

: Tramadol is a synthetic analog of codeine used to treat pain of moderate to severe intensity and is reported to have neurotoxic potential. At therapeutic dose, tramadol does not cause major side effects in comparison to other opioid analgesics, and is useful for the management of neurological problems like anxiety and depression. Long term utilization of tramadol is associated with various neurological disorders like seizures, serotonin syndrome, Alzheimer’s disease and Parkinson’s disease. Tramadol produces seizures through inhibition of nitric oxide, serotonin reuptake and inhibitory effects on GABA receptors. Extensive tramadol intake alters redox balance through elevating lipid peroxidation and free radical leading to neurotoxicity and produces neurobehavioral deficits. During Alzheimer’s disease progression, low level of intracellular signalling molecules like cGMP, cAMP, PKC and PKA affect both learning and memory. Pharmacologically tramadol produces actions similar to Selective Serotonin Reuptake Inhibitors (SSRIs), increasing the concentration of serotonin, which causes serotonin syndrome. In addition, tramadol also inhibits GABAA receptors in the CNS has been evidenced to interfere with dopamine synthesis and release, responsible for motor symptoms. The reduced level of dopamine may produce bradykinesia and tremors which are chief motor abnormalities in Parkinson’s Disease (PD).

scholarly journals Global Burden of Headache Disorders in Children and Adolescents 2007–2017

2020 ◽  
Vol 18 (1) ◽  
pp. 250
Author(s):  
Matilde Leonardi ◽  
Licia Grazzi ◽  
Domenico D’Amico ◽  
Paolo Martelletti ◽  
Erika Guastafierro ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Tension Type Headache ◽  
Global Burden ◽  
Specific Information ◽  
Headache Disorders ◽  
Substantial Impact ◽  
Public Health Policies ◽  
School Activities ◽  
Type Headache ◽  
Years Lived With Disability

Headache disorders are prevalent and disabling conditions impacting on people of all ages, including children and adolescents with substantial impact on their school activities and leisure time. Our study aims to report specific information on headaches in children and adolescents based on the Global Burden of Disease (GBD) study, that provides estimates for incidence, prevalence, fatal and non-fatal outcomes. We relied on 2007 and 2017 GBD estimates for prevalence and Years Lived with Disability (YLDs) at the global level and in WHO regions. The results show that, migraine and tension-type headache (TTH) together account for 37.5% of all-cause prevalence and for 7% of all-cause YLDs. Over the past decade, prevalence rates showed a mild increase of TTH in all ages and of migraine alone for adolescents. The YLDs increased among females of all ages with some regional differences that might be connected to the unequal availability of effective acute and prophylactic treatments across world regions. GBD data support the need to promote public health policies and strategies including diagnosis, pharmacological and non-pharmacological treatments that are expected to help reduce the disability and burden associated to migraine and TTH among children and adolescents.

Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study

Cephalalgia ◽  
2021 ◽  
pp. 033310242110292
Author(s):  
Isabella Neri ◽  
Daniela Menichini ◽  
Francesca Monari ◽  
Ludovica Spanò Bascio ◽  
Federico Banchelli ◽  
...  
Keyword(s):  
Migraine With Aura ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Migraine Without Aura ◽  
Perinatal Outcomes ◽  
First Trimester ◽  
Tension Type Headache ◽  
Headache Disorders ◽  
Aneuploidy Screening ◽  
Type Headache

Objective This study aims to investigate pregnancy and perinatal outcomes in women with tension-type headache, migraine without aura and migraine with aura by comparing them to women without any headache disorders. Study design Prospective cohort study including singleton pregnancies attending the first trimester aneuploidy screening at the University Hospital of Modena, in Northern Italy, between June 2018 and December 2019. Results A total of 515 consecutive women were included and headache disorders were reported in 43.5% of them (224/515). Tension-type headache was diagnosed in 24.3% of the cases, while 14% suffered from migraine without aura and 5.2% from migraine with aura. Birthweight was significantly lower in women affected by migraine with aura respective to other groups, and a significantly higher rate of small for gestational age infants was found in tension-type headache (10.4%) and in migraine with aura (24.9%) groups respective to the others (p < 0.001). Moreover, the admission to the neonatal intensive care unit was significantly higher in all the headache groups (p = 0.012). Multivariate analysis showed that women presenting tension-type headache (OR 4.19, p = 0.004), migraine with aura (OR 5.37, p = 0.02), a uterine artery pulsatility index >90th centile (OR 3.66, p = 0.01), low multiple of the median (MoM) of Pregnancy-associated plasma protein-A (PAPP-A) (OR 0.48, p = 0.05) and high MoM of Inhibin-A (OR 3.24, p = 0.03) at first trimester, are independently associated with the delivery of small for gestational age infants when compared to women without headache disorders. Conclusion Migraine with aura and tension type headache expose women to an increased risk of delivering small for gestational age infants, in association with some utero-placenta markers evaluated at first trimester. These women with headache disorders have an additional indication to undergo first trimester aneuploidy screening and would possibly benefit from specific interventions.

Sign in / Sign up

Export Citation Format

Share Document